In patients with diabetes and multivessel coronary artery disease undergoing percutaneous coronary intervention, ticagrelor ...

BARCELONA, Spain—In patients with acute coronary syndromes (ACS), the oral, reversible antiplatelet agent ticagrelor is superior to clopidogrel in reducing ischemic events, without any increase in ...

Despite a higher incidence of dyspnea among patients with acute coronary syndromes (ACS) on ticagrelor compared with clopidogrel, the side effect is usually not serious and resolves spontaneously or ...

The antiplatelet agent ticagrelor (Brilinta/Brilique, AstraZeneca) demonstrated bactericidal activity against antibiotic-resistant gram-positive bacteria that pose a threat to human health, including ...

Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. At 12 ...

Learn everything you need to know about Ticagrelor-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

After one month of dual antiplatelet therapy (DAPT) with aspirin and ticagrelor (Brilinta) post-percutaneous coronary intervention for an acute coronary syndrome, dropping aspirin cut bleeding risk ...

Bentracimab effectively reversed ticagrelor's antiplatelet effects, restoring platelet function in minutes for most patients in urgent situations. The REVERSE-IT trial showed 94.3% of patients ...

The appraisal committee reviewed the data available on the clinical and cost effectiveness of extended therapy with ticagrelor 60 mg twice daily plus aspirin (hereafter referred to as ticagrelor), ...